Mounjaro vs Biopatid — Which to Choose?
Both claim tirzepatide. The difference is in manufacturer, clinical evidence, regulatory status, and price.
Full Comparison Table
| Parameter | Mounjaro | Biopatid |
|---|---|---|
| Active ingredient | ✅ Tirzepatide | Claims tirzepatide (unconfirmed) |
| Manufacturer | Eli Lilly (USA) | UNIKKA PHARMA, distrib. Biopell Medical |
| Mechanism of action | ✅ GLP-1 + GIP (confirmed) | Claims GLP-1 + GIP |
| Clinical evidence | ✅ SURMOUNT-1: -22.5% (2,539 participants) | No proprietary RCTs |
| Administration frequency | Once weekly | Once weekly |
| Dosing | 2.5–15 mg | From 2.5 mg (40/60 mg vials) |
| Cost per 1 mg | ✅ ~492–575 ₴/mg (KwikPen) | ~530–800 ₴/mg (60 mg vial) |
| Side effects | GI discomfort 5-10% | No proprietary data |
| Availability | Through DOZA | Check availability |
| FDA/EMA registration | ✅ ✅ FDA 2022, EMA 2022 | ❌ Not registered |
| National Drug Registry | ❌ Not listed | ❌ Not listed |
| Proprietary RCTs | ✅ ✅ SURMOUNT-1 (2,539 participants) | ❌ Not conducted |
Key Differences
Same molecule
Both claim tirzepatide. Mounjaro is the original by Eli Lilly. Biopatid is by UNIKKA PHARMA.
Clinical evidence
Mounjaro: SURMOUNT-1, 2,539 participants, -22.5%. Biopatid: no proprietary studies.
Price vs clinical evidence
At working doses the per-mg price is comparable, but Mounjaro has FDA approval and SURMOUNT-1.
Real Cost of Treatment
Biopatid is positioned as a "cheaper alternative." The price depends on the dose.
Mounjaro (Eli Lilly)
- KwikPen 2.5 mg — from 17,000 ₴
- KwikPen 10 mg — from 23,000 ₴
- KwikPen 15 mg — from 29,500 ₴
- FDA/EMA, SURMOUNT-1
Biopatid (UNIKKA PHARMA)
- 10 mg vial — ~9,000 ₴
- 40 mg vial — ~32,000–35,000 ₴
- 60 mg vial — ~31,000–48,000 ₴
- No registration, no RCTs
Prices are approximate, May 2026. At starting dose, Biopatid is cheaper.
Biopatid: Facts for Your Decision
What is known
- •Claimed active ingredient — tirzepatide
- •Manufacturer — UNIKKA PHARMA (Brazil)
- •Distribution — Biopell Medical
- •Starting price lower than Mounjaro
- •At working doses the per-mg price is comparable
What is unknown
- •API source — not disclosed
- •No proprietary RCTs
- •Safety studies not published
- •No regulatory registration
- •Eli Lilly states it does not supply tirzepatide to third-party manufacturers
DOZA provides this information for an informed decision.
Independent Verdict
Mounjaro (Eli Lilly) — the only tirzepatide product with clinical evidence, FDA and EMA approval.
Biopatid (UNIKKA PHARMA) — claims the same active ingredient but lacks studies and registration.
Why experts are cautious about Biopatid
- ⚠️ Tirzepatide is patented by Eli Lilly until 2036
- ⚠️ Eli Lilly does not supply API to third-party manufacturers
- ⚠️ No safety publications for Biopatid
- ⚠️ Not registered with National Drug Registry, FDA, or EMA
We provide the facts. The decision is yours and your doctor''s.
Mounjaro vs Biopatid — Detailed Comparison
Mounjaro — Eli Lilly product, FDA 2022, dual GLP-1+GIP agonist, -22.5% weight loss.
Biopatid — UNIKKA PHARMA, Biopell Medical, no proprietary RCTs.
Both are available in the DOZA catalog. See also Mounjaro vs Ozempic and Ozempic vs Biopatid. DOZA Research Policy.
External sources on tirzepatide
- • EviDoc (Україна) — "БІОПАТІД: коли фейк видають за революцію у схудненні"
- • Reuters (Apr 2025) — Eli Lilly cease-and-desist
- • Reuters (Jan 2025) — Eli Lilly lawsuit
- • GOV.UK — MHRA counterfeit warning
- • HPRA (Ireland) — counterfeit tirzepatide pens
- • NBC News / WHO — counterfeit warnings
DOZA publishes sources for transparency.
FAQ: Mounjaro and Biopatid
Mounjaro has SURMOUNT-1 clinical evidence. Biopatid is more affordable but lacks proprietary studies.
DOZA Specialist
Take a free test
2 minIn 2 minutes, find out which program suits you best. Personalized weight loss and cost estimate.